United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read Pharma Industry News Merck advances pimicotinib in China as Center for Drug Evaluation accepts TGCT marketing application following pivotal Phase 3 data Merck’s TGCT treatment pimicotinib moves closer to approval in China after CDE accepts marketing application; global filings planned next. byPallavi MadhirajuJune 10, 2025